ARQT — Arcutis Biotherapeutics, Inc. stock price, charts and financials

Latest market price

25.38

-1.08-4.08%

Overview Short InterestFilings

ARQTQT58Arcutis Biotherapeutics, Inc.·NASDAQ

Overview Short InterestFilings

25.38-4.08%

News

Down 4.1% — RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study (Yahoo).

Medium confidence

Loading chart...

Signal & projected range

Insider selling clusterHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

DYN-5.26%$17.11 RCUS-1.17%$25.24 DNLI-2.04%$19.72 LEGN+0.17%$17.61 QURE-0.20%$44.00 MBX-1.53%$62.91 CLDX-1.90%$38.24 TARS-1.19%$78.09

Snapshot

Index	-	P/E	120.86	EPS (ttm)	0.21	Insider Own	18.09%	Shs Outstand	125.08M	Perf Week	6.24%

Market Cap	3.19B	Forward P/E	19.14	EPS next Y	1.33	Insider Trans	-0.53%	Shs Float	110.19M	Perf Month	-4.08%

Enterprise Value	3.05B	PEG	2.06	EPS next Q	0.17	Inst Own	-	Short Float	15.03%	Perf Quarter	-3.17%

Income	28.00M	P/S	6.84	EPS this Y	136.73%	Inst Trans	-	Short Ratio	9.88	Perf Half Y	10.78%

Sales	464.00M	P/B	14.36	EPS next Y	166.67%	ROA	5.84%	Short Interest	16.56M	Perf YTD	-12.60%

Book/sh	1.77	P/C	13.28	EPS next 5Y	58.73%	ROE	15.05%	52W High	31.77 -20.11%	Perf Year	48.07%

Cash/sh	1.91	P/FCF	76.31	EPS past 3/5Y	-	ROIC	9.95%	52W Low	16.57 53.17%	Perf 3Y	238.40%

Dividend Est.	-	EV/EBITDA	69.31	Sales past 3/5Y	354.68% -	Gross Margin	91.14%	Volatility	7.09% 4.38%	Perf 5Y	20.00%

Dividend TTM	-	EV/Sales	6.57	EPS Y/Y TTM	118.10%	Oper. Margin	7.38%	ATR (14)	1.21	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	2.67	Sales Y/Y TTM	135.53%	Profit Margin	6.15%	RSI (14)	52.55	Recom	2.17

Dividend Gr. 3/5Y	-	Current Ratio	2.92	EPS Q/Q	184.62%	SMA20	3.82%	Beta	1.54	Target Price	38.00

Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	58.54%	SMA50	-2.17%	Rel Volume	9.04	Prev Close	26.46

Employees	354	LT Debt/Eq	0.03	Earnings	Oct 27	SMA200	-0.01%	Avg Volume	2.11M	Price	25.38

IPO Date	Jan 31, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	99.73% 9.26%	Net Debt/EBITDA	1.81	Volume	19,100,379	Change	-4.08%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-06-26	Reiterated	Morgan Stanley	Overweight	$51 → $38
Aug-06-26	Reiterated	Guggenheim	Buy	$38
Feb-26-26	Reiterated	HC Wainwright & Co.	Buy	$30 → $34
Nov-28-25	Reiterated	Mizuho	Outperform	$32 → $37
Oct-30-25	Reiterated	Goldman Sachs	Neutral	$37 → $29
Oct-29-25	Reiterated	H.C. Wainwright	Buy	$22 → $30
Oct-29-25	Reiterated	Mizuho Securities	Outperform	$18 → $32
Mar-11-25	Reiterated	Jefferies	Buy	$19
Dec-30-24	Initiated	H.C	Buy	$19
May-15-24	Reiterated	Mizuho	Buy	$8.00 → $18

Latest News· Times ET

Sep-17-26

Sep-17-2610:48AM

RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma StudyYahoo

07:40AM

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?zacks.com

Sep-16-26

Sep-16-2612:31PM

Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com

Sep-07-26

Sep-07-2606:23AM

Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth with Improving FundamentalsChartMill

Sep-04-26

Sep-04-2607:15PM

Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600Yahoo

12:00PM

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Sep-02-26

Sep-02-2612:00PM

Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conferenceglobenewswire.com

Aug-28-26

Aug-28-2608:01AM

Here's Why You Should Add ARQT Stock to Your Portfolio Nowzacks.com

Aug-27-26

Aug-27-2601:31AM

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigenzacks.com

Aug-26-26

Aug-26-2611:39PM

Bamco Inc. NY Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQTdefenseworld.net

07:20AM

5 Biotech Stocks Worth Adding to Your Portfolio Nowzacks.com

Aug-25-26

Aug-25-2607:01AM

Insider Decision Unfolding At Arcutis Biotherapeutics: Terrie Curran Exercises Options, Resulting In $18KBenzinga

Aug-23-26

Aug-23-2611:53PM

382,682 Shares in Arcutis Biotherapeutics, Inc. $ARQT Bought by Deutsche Bank AGdefenseworld.net

Aug-20-26

Aug-20-2609:47AM

Arcutis Biotherapeutics’ Subsidiary Arcutis Canada Secures Health Canada Approval For Roflumilast Cream In Pediatric Atopic Dermatitis PatientsBenzinga

Aug-14-26

Aug-14-2606:11AM

Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating FundamentalsChartMill

Company

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	464	376	197	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	42	37	19	—	—	—	—	—	—
Gross Profit	424	339	177	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	297	275	229	—	—	—	—	—	—
Research and Development	91	77	76	—	—	—	—	—	—
Other Operating Expense	0	0	1	—	—	—	—	—	—
Operating Income	34	-12	-128	—	—	—	—	—	—
Interest Expense	13	12	27	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	8	9	16	—	—	—	—	—	—
Net Income Before Taxes	29	-15	-139	—	—	—	—	—	—
Income Taxes	0	1	1	—	—	—	—	—	—
Consolidated Net Income	28	-16	-140	—	—	—	—	—	—
Net Income From Continuing Operations	28	-16	-140	—	—	—	—	—	—
Net Income	28	-16	-140	—	—	—	—	—	—
EPS (Recurring)	0.22	-0.13	-1.16	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	0.22	-0.13	-1.16	—	—	—	—	—	—
EPS (Diluted)	0.21	-0.13	-1.16	—	—	—	—	—	—
EBITDA	44	2	-110	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	120.86	—	—	—	—	—	—	—	—
Price To Sales Ratio	7.17	9.81	8.56	—	—	—	—	—	—
Gross Margin	91.38	90.16	89.85	—	—	—	—	—	—
Operating Margin	7.33	-3.19	-64.97	—	—	—	—	—	—
Net Margin	6.03	-4.26	-71.07	—	—	—	—	—	—
Shares Outstanding	131	127	121	—	—	—	—	—	—
Market Capitalization	3,325	3,688	1,686	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Matsuda Masaru	See Remarks	Sep 16 '26	Sale	25.00	3,674	91,853	112,508	Sep 18
Welgus Howard G.	Director	Sep 15 '26	Option Exercise	7.93	4,096	32,475	40,571	Sep 17
Welgus Howard G.	Director	Sep 15 '26	Sale	24.18	4,730	114,371	35,841	Sep 17
Matsuda Masaru	See Remarks	Sep 08 '26	Sale	25.03	9,989	249,986	116,182	Sep 10
Curran Terrie	Director	Aug 27 '26	Option Exercise	8.30	38,200	317,180	50,578	Aug 28
Curran Terrie	Director	Aug 27 '26	Sale	25.03	27,052	677,095	23,526	Aug 28
Curran Terrie	Director	Aug 20 '26	Option Exercise	7.51	1,072	8,051	24,598	Aug 24
Curran Terrie	Director	Aug 20 '26	Sale	26.04	1,072	27,912	23,526	Aug 24
Burnett Patrick	See Remarks	Aug 19 '26	Sale	27.00	1,697	45,819	117,592	Aug 21
Welgus Howard G.	Director	Aug 17 '26	Option Exercise	7.93	4,096	32,475	41,205	Aug 19
Welgus Howard G.	Director	Aug 17 '26	Sale	26.18	4,730	123,835	36,475	Aug 19
Burnett Patrick	See Remarks	Aug 12 '26	Option Exercise	3.64	6,700	24,388	125,989	Aug 13
Burnett Patrick	See Remarks	Aug 12 '26	Sale	26.08	6,700	174,767	119,289	Aug 13
Burnett Patrick	See Remarks	Aug 11 '26	Sale	26.52	8,300	220,129	119,289	Aug 13
Burnett Patrick	See Remarks	Aug 11 '26	Option Exercise	3.64	8,300	30,212	127,589	Aug 13

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.